USA flag logo/image

An Official Website of the United States Government

Portable nanofluidic aptamer-SERS instrument for measurement of chemical…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
R43ES022303
Solicitation Year:
2012
Solicitation Topic Code:
NIEHS
Solicitation Number:
ES12-004
Small Business Information
BIOTEX, INC.
8058 EL RIO ST HOUSTON, TX -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2012
Title: Portable nanofluidic aptamer-SERS instrument for measurement of chemical exposure
Agency: HHS
Contract: 1R43ES022303-01
Award Amount: $248,891.00
 

Abstract:

DESCRIPTION (provided by applicant): Project Summary The goal of this NIH-SBIR Phase I proposal is to develop a new point-of-care (POC) detection platform and methodology for assessment of human exposure to hazardous environmental compounds in the bloodstream. Because the mechanisms of transport of such chemicals into the body, their differing stabilities, and elimination are difficult to model, if possible, it is much more straightforward to assay for these compounds in the body rather than in the environment. The primary innovations in our approach are that a novel optical micro- to nano-fluidic device will be used along with unique aptamers and Raman reporter molecules to simultaneously measure several classes of compounds in a multiplexed fashion. The opto-fluidic device is an extremely sensitive surface enhanced Raman spectroscopy (SERS) nanochannel cartridge that was invented at Texas AandM University by professors Jun Kameoka and Gerard Cot . The aptamer functionalization chemistry as well as the overall integrated product will be developed at BioTex, Inc. The device being developed provides signal enhancements equal to or exceeding 1014 at the entrance to the nanochannel, enabling rapid quantification of femtomolar or smaller levels of targets in fluids. This SERS-based nanofluidic platform has been demonstrated through several publications and so the key question that need to be addressed by the company are can the aptamer chemistry perform as intended in progressively complex media including whole blood with this platform and can the platform be optimized for this application. Thus, the specific aims of this research are to develop the aptamer assay for specifically detecting model polychlorinated biphenyls (PCBs), bisphenol-A (BPA), and model phthalates. The resonant-SERS reporting and nanofluidic concentrator employed have the potential to provide orders-of-magnitude improved sensitivity over standard fluorescence and without the complicated multistep tasks of ELISA or full analytical chemistry analysis such as chromatography and mass spectrometry. PUBLIC HEALTH RELEVANCE: Project Narrative The goal of this research is to develop a new point-of-care (POC) detection platform and methodology for assessment of biological exposure to harmful chemical compounds. With the potential to greatly improve the sensitivity and ease of such measurements, the end-product of this research is expected to have considerable impact allowing toxicologists, environmental health professionals, and clinicians the ability to correlate the effects of toxic chemicals to disease states.

Principal Investigator:

George W. Jackson
713-741-0111
bill@biotexmedical.com

Business Contact:

Ashok Gowda
713-741-0111
ashok@biotexmedical.com
Small Business Information at Submission:

BIOTEX, INC.
8058 EL RIO ST HOUSTON, TX -

EIN/Tax ID: 174282404
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No